Received Oct 2, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | IM |
Boostrix - needle size, used the 5/8 inch needle instead of the 1 inch needle; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incorrect vaccine administration technique in a 65-year-old patient who received DTPa (Reduced antigen) (Boostrix) for prophylaxis. On 07-SEP-2025, the patient received Boostrix (intramuscular, unknown deltoid). On 07-SEP-2025, an unknown time after receiving Boostrix, the patient experienced incorrect vaccine administration technique (Verbatim: Boostrix - needle size, used the 5/8 inch needle instead of the 1 inch needle). The outcome of the incorrect vaccine administration technique was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 08-Sep-2025 A pharmacist reported that yesterday a patient received a Boostrix dose. The dose was administered in the deltoid muscle but they used the 5/8 inch needle instead of the 1 inch needle. The HCP asked if the patient should be revaccinated and what would be the adverse reactions if the patient receive and extra dose.